Год выпуска: 2012 Издательство: Страниц: 624 ISBN: 0199742995
Описание
The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing...
Привет, Виталий. Примите, пожалуйста, мои восхищения Вами по поводу курсовика, который Вы мне сегодня прислали. Вы не представляете, как чудовищно он контрастирует с той работой, которую сегодня мне показывал мой однокурсник. То, что я увидел достойно быть настольным пособием по сопровождению подобных работ. Нас не учили так красиво делать.